Skip to main content

Retevmo Disease Interactions

There are 5 disease interactions with Retevmo (selpercatinib).

Moderate

Selpercatinib (applies to Retevmo) bleeding

Moderate Potential Hazard, Moderate plausibility.

Serious including fatal hemorrhagic events can occur with the use of selpercatinib. Care should be exercised when using this agent in patients with bleeding disorders. It is recommended to permanently discontinue treatment in patients with severe or life-threatening hemorrhage.

References

  1. "Product Information. Retevmo (selpercatinib)." Lilly, Eli and Company (2020):
Moderate

Selpercatinib (applies to Retevmo) hypertension

Moderate Potential Hazard, Moderate plausibility.

Selpercatinib may cause hypertension and therapy should not be initiated in patients with uncontrolled hypertension. Care should be exercised when using this agent in hypertensive patients. Optimize blood pressure before starting treatment. It is recommended to monitor blood pressure after 1 week, and regularly as clinically indicated. Initiate or adjust anti-hypertensive therapy as appropriate. Withhold, reduce dose, or permanently discontinue treatment based on the severity.

References

  1. "Product Information. Retevmo (selpercatinib)." Lilly, Eli and Company (2020):
Moderate

Selpercatinib (applies to Retevmo) liver dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Selpercatinib is metabolized predominantly by CYP450 3A4. The dose of selpercatinib should be reduced in patients with severe hepatic impairment. No dosage modification is recommended for patients with mild or moderate hepatic impairment. Serious hepatic adverse reactions have been reported in patients treated with selpercatinib. Monitor ALT and AST before starting therapy with selpercatinib, every two weeks during the first three months, then monthly thereafter and as clinically indicated. It is recommended to withhold, reduce dose or permanently discontinue treatment based on the severity of selpercatinib-related adverse reactions in patients with hepatic impairment.

References

  1. "Product Information. Retevmo (selpercatinib)." Lilly, Eli and Company (2020):
Moderate

Selpercatinib – arrhythmias

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Hypokalemia, Magnesium Imbalance, Hypocalcemia, Electrolyte Abnormalities, Thyroid Disease

Selpercatinib can cause concentration-dependent QT interval prolongation. It is recommended to assess QT interval, electrolytes, and TSH at baseline and periodically during treatment and to adjust treatment based upon risk factors. Correct hypokalemia, hypomagnesemia, and hypocalcemia before initiating treatment. Monitor regularly for these laboratory values and correct them as clinically appropriate. Withhold, reduce the dose or permanently discontinue treatment based on the severity.

References

  1. "Product Information. Retevmo (selpercatinib)." Lilly, Eli and Company (2020):
Moderate

Selpercatinib – renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

The use of selpercatinib may increase serum creatinine. It is recommended to consider alternative markers of renal function if persistent elevations in serum creatinine are observed. No dosage modification is recommended for patients with mild to moderate renal impairment. Exercise caution when using this agent in patients with severe renal impairment or end-stage renal disease as the recommended dosage has not been established for these patients.

References

  1. "Product Information. Retevmo (selpercatinib)." Lilly, Eli and Company (2020):

Retevmo drug interactions

There are 588 drug interactions with Retevmo (selpercatinib).

Retevmo alcohol/food interactions

There are 2 alcohol/food interactions with Retevmo (selpercatinib).


Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.